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Abstract
Gastric cancer is the second leading cause of cancer-related death worldwide. The identification of new cancer biomarkers is
necessary to reduce the mortality rates through the development of new screening assays and early diagnosis, as well as
new target therapies. In this study, we performed a proteomic analysis of noncardia gastric neoplasias of individuals from
Northern Brazil. The proteins were analyzed by two-dimensional electrophoresis and mass spectrometry. For the
identification of differentially expressed proteins, we used statistical tests with bootstrapping resampling to control the type
I error in the multiple comparison analyses. We identified 111 proteins involved in gastric carcinogenesis. The computational
analysis revealed several proteins involved in the energy production processes and reinforced the Warburg effect in gastric
cancer. ENO1 and HSPB1 expression were further evaluated. ENO1 was selected due to its role in aerobic glycolysis that may
contribute to the Warburg effect. Although we observed two up-regulated spots of ENO1 in the proteomic analysis, the
mean expression of ENO1 was reduced in gastric tumors by western blot. However, mean ENO1 expression seems to
increase in more invasive tumors. This lack of correlation between proteomic and western blot analyses may be due to the
presence of other ENO1 spots that present a slightly reduced expression, but with a high impact in the mean protein
expression. In neoplasias, HSPB1 is induced by cellular stress to protect cells against apoptosis. In the present study, HSPB1
presented an elevated protein and mRNA expression in a subset of gastric cancer samples. However, no association was
observed between HSPB1 expression and clinicopathological characteristics. Here, we identified several possible biomarkers
of gastric cancer in individuals from Northern Brazil. These biomarkers may be useful for the assessment of prognosis and
stratification for therapy if validated in larger clinical study sets.
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Introduction
Gastric cancer (GC) is the fourth most common cancer and the
second leading cause of cancer-related death worldwide [1]. The
overall relative 5-year survival rate is currently less than 20% [2].
In Northern Brazil, GC is the second most frequent neoplasia
among males and the third in females [3]. In Para´ State, Northern
Brazil, the 5-year survival rate is about 9–10% [4].
The two main tumor sites of GC are cardia (proximal) and
noncardia (distal). The cardia GC affects five times more men than
women [5]. In addition, the incidence rates of cardia GC are
relatively high in the professional classes [6]. In contrast, the
noncardia GC has a male-to-female ratio of approximately 2:1
and the incidence rises progressively with age, with a peak
incidence between 50 and 70 years [7]. The risk factors for
noncardia GC include Helicobacter pylori infection, low socioeco-
nomic status, smoking, intake of salty and smoked food, and low
consumption of fruits and vegetables [8]. Over the last few
decades, the incidence of noncardia GC has substantially declined
in developed regions of the world. However, this subtype still
constitutes the majority of GC cases worldwide and remains
common in many geographic regions, including China, Japan,
Eastern Europe and Central/South Americas [8]. The under-
standing of GC biology and the identification of cancer
biomarkers are necessary to reduce the mortality rates through
cancer screenings in high-risk populations, to increase early
diagnosis, and to develop new target therapies.
GC, as other neoplasias, is thought to result from a combination
of environmental factors and the accumulation of generalized and
specific genetic and epigenetic alterations, which affect oncogenes,
tumor suppressor genes, and control genomic instability. Several
genes/proteins have been proposed as GC biomarkers. In the
multistage gastric carcinogenesis, alterations of the oncogenes
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MYC, KRAS2, CTNNB1, ERBB2, FGFR2, CCNE1 and HGFR,
as well as of the tumor suppressors TP53, APC, RB, DCC,
RUNX3 and CDH1 have been so far reported (see reviews
[9,10]). Although the deregulation of these genes/proteins has
been intensively studied in GC, a more complete profiling is
necessary to understand the carcinogenesis process.
The last decade in life sciences was deeply influenced by the
development of the ‘‘Omics’’ technologies (genomics, transcrip-
tomics, proteomics, and metabolomics) which aim to depict a
global view of biological systems and the understanding of the
living cell [11]. Since proteins are ultimately responsible for the
malignant phenotype, proteomic analyses may reflect the func-
tional state of cancer cells, and therefore have distinct advantages
over genomics and transcriptomics studies [12]. Moreover,
proteins are currently the main target molecules of anticancer
drugs [13].
Some proteomic-based studies were previously performed in
human primary gastric tumors (see review [14]). However, most of
these studies analyzed tumors of individuals from Asian population
and, thus, may not reflect the distinct biological and clinical
behaviors among GC processes. GC is marked by global variations
in incidence, etiology, natural course, and management [15].
Although, about 90% of stomach tumors are adenocarcinomas
[7], several factors lead to biologically and clinically GC subsets:
antecedent tumorigenic conditions, such as Helicobacter pylori
gastritis and other chronic gastric pathologies; location of the
primary tumor (cardia and noncardia region); subtypes of
adenocarcinoma (diffuse, intestinal, or mixed [16]); ethnicity of
the afflicted population (differing levels of susceptibility and
aggressiveness of the tumors); and a predictive biomarker (ERBB2)
[15]. Thus, the term ‘‘gastric cancer’’ is used to describe several
neoplasias that affect the stomach region.
In the present study, we compared the expression profile of
noncardia GC and the matched non-neoplastic gastric tissue of
individuals from Northern Brazil (all with H. pylori infection), and
identified a protein signature that was differentially expressed
between the two groups by a two-dimensional electrophoresis (2-
DE) method. To screen proteins related to the progression of
gastric carcinogenesis, we also compared non-neoplastic gastric
tissues with GC samples of individuals with and without lymph
node metastases. For the selection of differentially expressed
proteins, we used a statistical parametrics test with bootstrapping
resampling. We have undertaken a comprehensive computational
analysis of tissue proteomic data to discover pathways and
networks involved in gastric oncogenesis and progression. The
possible associations among enolase 1 (ENO1) and heat shock
27 kDa protein 1 (HSPB1) gene and protein expression, and
clinicopathological characteristics were also evaluated in individ-
uals from Northern Brazil. These two proteins have been reported
frequently as deregulated molecules in previous GC proteomic
studies in other populations. However, they were never evaluated
in a Brazilian population.
Methods
Clinical specimens
For protein profiling analysis, noncardia GC samples and
corresponding non-neoplastic gastric tissue (distant location of
primary tumor; control group) were collected from 15 patients.
Additional paired samples were included for western blot and real
time quantitative PCR (RT-qPCR) analyses. Dissected tissue
specimens were snap-frozen in liquid nitrogen after surgical
dissection and stored at 280uC until use. All the gastric samples
were obtained surgically from Joa˜o de Barros Barreto University
Hospital (HUJBB) in Para´ State, Northern Brazil. In Para´ State,
the human population is composed of interethnic crosses between
three main origin groups: European (mainly represented by the
Portuguese), Africans, and Amerindians [17]. All patients had
negative histories of exposure to either chemotherapy or
radiotherapy before surgery and there was no other co-occurrence
of diagnosed cancers. Written informed consent with approval of
the ethics committee of HUJBB was obtained from all patients
prior to specimen collection.
All samples were classified according to Laure´n [16] and tumors
were staged using standard criteria by TNM staging [18]. The
presence of H. pylori, a class I carcinogen, in gastric samples was
detected by PCR assay for the urease gene [19] and for its
virulence factor vacuolating cytotoxin (CagA) [20] using the DNA
purified simultaneously with the proteins and the mRNA. In each
PCR experiment, positive and negative controls were included.
To reduce sample heterogeneity, the 2-DE analysis included
only noncardia GC and gastric samples presenting H. pylori
infection CagA+, which seems to be frequent in our population
(unpublished data). Table 1 shows the clinicopathological charac-
teristics of samples used for protein profiling analysis.
Protein, mRNA and DNA purification
Total protein, mRNA, and DNA were simultaneously isolated
from gastric tissue samples using the AllPrep DNA/RNA/Protein
Kit (Qiagen, Germany) according to the manufacturer’s instruc-
tions. The protein pellet was dissolved in buffer containing 7 M
urea, 2 M thiourea, 4% CHAPS, 50 mM DTT, 1% Protease
Inhibitor Cocktail (Sigma), and 0.5% of each Phosphatase
Inhibitor Cocktail 1 and 2 (Sigma-Aldrich, USA). Protein
concentration was determined by the method of Bradford
(Sigma-Aldrich, USA). RNA concentration and quality were
determined using a NanoDrop spectrophotometer (Kisker,
Germany) and 1% agarose gels. Samples were stored at 280uC
until use.
2-DE proteomics profiling
Proteins were separated by 2-DE [21]. Protein samples (300 mg)
were loaded on IPG strips (pH 3–10 L, 18 cm, GE Healthcare,
USA). The strips were rehydrated for 12 h at 50 V. The isoelectric
focusing was carried out using the following program: 200 V 2 h,
300 V 30 min, 500 V 30 min, 1000 V 1 h, 8000 V 1.5 h and
80,000 Vh. The focused strips were reduced with 50 mM DTT
and alkylated with 100 mM iodoacetamide in buffer containing
6 M urea, 50 mM Tris-HCl (pH 8.8), 30% glycerol, 2% SDS, and
trace bromophenol blue. For secondary electrophoresis, the
treated strips were loaded on the top of 12.5% SDS-PAGE
(200 mm) together with the PeppermintStickTM Phosphoprotein
Molecular Weight Standards (Invitrogen, USA). In all experi-
ments, GC and paired control samples were performed simulta-
neously. All 2-DE gels were performed in duplicate.
The proteins on the 2-DE gels were visualized using SYPROH
Ruby Gel Stain (Invitrogen, USA) following the manufacturer’s
recommendations. Images of gels stained with SYPROH Ruby
were scanned with a 582 nm excitation and a 610 nm 30 bandpass
emission filter on a Typhoon Trio imager (GE Healthcare, USA).
For spot excision and subsequent mass spectrometry analysis, the
gels were visualized with Coomassie Brilliant Blue G250 staining.
Image analysis and spot identification
Gel images were analyzed with the PDQuest Advanced software
version 8.0 (Bio-Rad, USA), according to the manufacturer’s
protocol. Automatic spot detection in each gel was verified by
visual inspection. Some spots were used as landmarks to align the
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images. The spot intensities were normalized to equalize the total
densities of each gel image using the Local Regression Model.
Normalized protein spot volumes in the proteomes were compared
among experimental groups.
We created two sets of analyses to identify differentially
expressed spots: (1) the comparison of protein expression between
tumor and matched control using paired T-test; (2) comparison of
protein expression among control samples, GC without lymph-
node metastasis, and GC with lymph-node metastasis using One-
Way Analysis of Variance for independent samples (one-way
ANOVA). In addition, post-hoc comparisons were performed with
Tukey’s test for normally distributed variables and with Games-
Howell for distributions where equal variances could not be
assumed. The parametric tests analyses were performed with
bootstrapping, a resampling method. The bootstrapping method
[22] provides a critical adjusted p-value, controlling a type I error
(false positive), reducing over-fit bias and validating the accuracy
estimates. The bootstrapping technique can provide a more
accurate and less conservative familywise error rate (FWER) than
standard methods (e.g., Bonferroni’s adjustment) for multicompar-
ison analyses [23]. We performed all the analyses to identify
differently expressed proteins based on 1000 bootstrap samples. In
all analyses, the confidence interval (CI) was 95% and p values less
than 0.05 were considered significant.
For protein identification by mass spectrometry, we filtered out
significant spots presenting a fold change below 1.5-fold in the
density between two experimental groups. These spots were
observed in less than 30% of the samples in a group [24].
Mass spectrometry analysis
The spots of interest were manually excised for subsequent mass
spectrometry analysis [25]. In addition, blank gel pieces from a
spot-free region, and reference spots (known marker proteins from
the 2-DE) were excised, served as controls for trypsin digestion,
and were run in parallel with the protein spots of interest. After
destaining and washing, the gel particles were subjected to in-gel
digestion with 20 ng/ml of Trypsin Gold (Mass Spectrometry
Grade, Promega Corporation, USA) in 25 mM ammonium
bicarbonate at 37uC overnight. Digested peptides were recovered,
placed in a Speed-vac centrifuge until dry, and were reconstituted
in 15 ml of 0.1% formic acid in water. The peptide mixture was
analyzed using C18 ultra-performance liquid chromatography
(UPLC, NanoAcquity, Waters, USA) coupled with ESI-quadru-
pole TOF mass spectrometer (ESI-QTOF Ultima, Waters/
Micromass, USA). The gradient was 0–80% acetonitrile in 0.1%
formic acid over 20 or 10 min. All MS/MS spectra were searched
against the IPIhuman 379 database using MASCOT search
engine (Matrix Science), accepting one missed tryptic cleavage and
carbamidomethyl (C) as fixed modification and oxidation (M) as
variable modifications. Peptide tolerance was 60.1 Da and MS/
MS tolerance was 60.1 Da. Highest confidence identification had
statistically significant search scores and protein identifications
were based on a minimum of 2 peptide hits.
Bioinformatics analysis
The identified proteins (from only the spots where one protein
was identified) were classified into groups according to subcellular
compartmentalization, biological process, and molecular function
based on the information annotated in the Gene Ontology (GO)
Consortium databases (http://www.geneontology.org/). This
classification analysis was performed using the DAVID functional
annotation tool (http://david.abcc.ncifcrf.gov/) [26]. The chro-
mosomal location of identified proteins was accessed using
BioMart data mining tool directly from Ensembl database
(http://www.ensembl.org/biomart/martview).
The PANTHER system (www.pantherdb.org/), MetaCore
software (GeneGo Inc.), and the Ingenuity Pathways Analysis
9.0 (IPA, Ingenuity Systems Inc.) were used for pathway, network,
and functional analyses of differentially expressed proteins. All
reported pathways and biological processes are listed according to
their GO enrichment score provided by the software packages as
2Log (p-values) and with a False Discovery Rate (FDR) of 0.05%.
The unsupervised clustering analysis was performed using
Pearson’s correlation of the normalized (z-score) values of all
significant differentially expressed proteins (unique ID by spot) of
30 samples in the analysis set. Heat maps were generated using the
Table 1. Clinicopathological characteristics of gastric cancer samples used for protein profiling analysis.
Patient Gender Age Laure´n classification TNM H. pylori – UreAa H. pylori – CagAa
T1 Male 55 Intestinal T1b-Sm Positive Positive
T2 Male 35 Intestinal pT3N3M Positive Positive
T3 Female 73 Diffuse pT1N0M Positive Positive
T4 Male 57 Diffuse pT2N1M Positive Positive
T5 Female 55 Intestinal pT4N1M Positive Positive
T6 Female 43 Intestinal pT4N1M Positive Positive
T7 Male 68 Intestinal pT3N1M Positive Positive
T8 Female 40 Intestinal pT2N0M Positive Positive
T9 Female 50 Intestinal pT1N0M Positive Positive
T10 Female 47 Intestinal pT3N2M Positive Positive
T11 Female 23 Diffuse pT3N1M Positive Positive
T12 Male 82 Intestinal pT3N1M Positive Positive
T13 Female 79 Intestinal pT1N0M Positive Positive
T14 Male 48 Intestinal pT2N1M Positive Positive
T15 Male 72 Intestinal pT3N0M Positive Positive
aH. pylori infection was also present in all corresponding non-neoplastic gastric samples.
doi:10.1371/journal.pone.0042255.t001
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Heatmap builder (http://ashleylab.stanford.edu/tools_scripts.
html) to arrange protein expression profiles and samples on the
basis of their similarity. Each colored cell on the two-dimensional
map represents the protein expression value of the sample.
Increasingly positive values are indicated by reds of increasing
intensity, and increasingly negative values by greens of increasing
intensity. Dendrograms on the top of the heat map show the
clustering of samples and on the side of the clustering by protein
expression.
ENO1 and HSPB1 expression
The protein and mRNA used for the ENO1 and HSPB1
expression analyses were purified simultaneously with the protein
sample used for 2-DE gels.
For western blot analysis, reduced protein (20 mg for ENO1 and
30 mg for HSBP1) of each sample was separated on 12.5%
homogeneous SDS-PAGE gel and electro-blotted to a PVDF
membrane (Hybond-P, GE Healthcare, USA). The PVDF
membrane was blocked with phosphate-buffered saline containing
0.1% Tween 20, 5% low fat milk and incubated overnight at 4uC
with corresponding primary antibodies to anti-ENO1 (sc-100812,
1:3000, Santa Cruz Biotechnology, USA), anti-HSBP1 (sc-13132,
1:1000, Santa Cruz Biotechnology, USA), and anti-ACTB (Ac-74,
1:3000, Sigma-Aldrich, USA). After extensive washing, a perox-
idase-conjugated secondary antibody was incubated for 1 h at
room temperature. Immunoreactive bands were visualized using
Western blotting Luminol reagent and the images were acquired
using an ImageQuant 350 digital image system (GE Healthcare,
Sweden). ACTB was used as a loading reference control.
For RT-qPCR analysis, the complementary DNA was synthe-
sized using High-Capacity cDNA Archive kit (Applied Biosystems,
Poland) according to the manufacturer’s protocol. All real-time
RT-qPCR assays were performed in triplicate for both target gene
(ENO1: Hs00361415_m1; HSPB1: Hs03044127_g1, Applied
Biosystems, USA) and internal controls (ACTB: Hs03023943_g1;
GAPDH: Hs99999905_m1, Applied Biosystems, USA) using
primers and TaqMan probes. Relative quantification (RQ) of
the gene expression was calculated according to Pfaffl method
[27]. A control sample was designated as a calibrator of each
paired tumor.
Statistical analysis of ENO1 and HSBP1 expression data
We first evaluated the normal distribution of all data using the
Shapiro-Wilk normality test to determine subsequent use of
appropriate tests for statistical comparison. ENO1 mRNA levels
and HSPB1 expression data were not normally distributed and
were transformed (z-score) for analysis. Paired T-test was
performed to compare the mean of ENO1 and HSPB1 protein
expression between control and GC samples. The associations
between clinicopathological parameters and the mean of ENO1
and HSPB1 expression were assessed using T-test for independent
samples. Chi-square test (x2) was also used to evaluate the
relationship between expression data and clinicopathological
factors. The correlation between the ENO1 and HSPB1 mRNA
and protein expression (western blot and 2-DE analyses) was
analyzed by Spearman test. In all analyses, the CI was 95% and p
values less than 0.05 were considered significant.
Results and Discussion
Proteomic analysis of gastric tissue
We analyzed the proteome of 15 noncardia GC samples – 6
without lymph node metastasis and 9 with lymph node metastasis
– and 15 matched control tissues (Table 1). Using 2-DE with pI
range of 3.0–10 and molecular range between 10 kDa and
120 kDa, about 1000 spots were clearly detected by gel and
subsequently analyzed for differential protein expression. Figure 1
shows representative gel images with the spots and their protein
ID. Some proteins were reflected by multiple spots most likely due
to posttranslational modification leading to shifts in the 2-DE gel.
Details of the protein identifications, theoretical pI value,
molecular weight, protein score, sequence coverage, number of
matched peptides, as well as average relative change and p-values
are shown in supplementary tables S1 and S2. These tables also
Figure 1. Representative 2-DE gel images of (A) gastric tumors and (B) non-neoplastic gastric samples. Proteins were resolved over the
pI range 3–10, followed by 12.5% SDS-PAGE and stained with SYPROH Ruby. The identified proteins that showed significantly altered expression in
gastric carcinogenesis are labeled with the respective protein IDs.
doi:10.1371/journal.pone.0042255.g001
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show which proteins were previously observed in GC proteomic
studies.
Although some proteomic-based studies were previously
performed in human primary gastric tumors, to our knowledge,
only three studies focus on noncardia GC [28,29,30]. Most GC
proteomic studies identified differentially expressed proteins based
only on a fold change between two conditions
[24,28,30,31,32,33,34,35]. Other previous GC proteomic studies
performed statistical analyses to compare the protein expression
between groups [29,36,37,38,39], but without controlling the type
I (false positive) error. It is interesting to note that we compared
the protein profiling of tumors and non-neoplastic samples using
parametric tests with bootstrapping for differentially expressed
protein identification. The resampling methods, commonly used in
microarray studies [40], have been used to make p-value
adjustments for multiple testing procedures which control the
FWER and take into account the dependence structure between
test statistics [41]. The objective is to create many sets of bootstrap
samples by resampling with the replacements from the original
data [22].
The comparison of tumor and control samples by paired T-test
and the use of bootstrapping revealed 133 spots that were
significantly altered with more than 1.5 fold change. Following a
Mascot database search using the acquired MS data, 97% of the
spots were identified. Among these spots, 18% were identified with
more than one protein. The analyses of the spots with a unique
identified proteins showed that 33 spots of 26 proteins were up-
regulated and 72 of 56 proteins were down-regulated in GC
samples compared to non-neoplastic tissue.
The comparison of tumor and control samples by one-way
ANOVA revealed 143 differentially regulated spots and 98% of
these were identified. We observed that 94 spots were common in
paired T-test and ANOVA analyses. Concerning the spots with a
unique identified protein, we observed that 54 proteins were
down-regulated and 9 were up-regulated in tumor without lymph
node metastasis relative to control samples. We also observed that
68 proteins were down-regulated and 15 were up-regulated in
tumors with lymph node metastasis compared to control samples.
We detected 38 proteins differentially expressed between non-
neoplastic samples and tumors independent of the lymph node
status.
Fourteen proteins presented significant alterations between
tumors with and without lymph node metastasis (Figure S1).
The expression of NNMT continually increased while ATP5H
and UQCRFS1 showed a continuous reduction from non-
neoplasia to tumorigenesis with lymph node metastasis. NNMT
was previously reported with elevated expression in GC compared
to non-neoplastic samples [24,42]. The reduced expression of
ATP5H and UQCRFS1 may be due to a lower dependence of
oxidative phosphorylation for energy production, due to the
Warburg effect in advanced state (see bioinformatics results
below).
Functional classification of differentially expressed
proteins in GC
The GeneGo biomarker analysis revealed that most of the
identified proteins predicted markers for gastrointestinal diseases,
Figure 2. The identified proteins were grouped into different classes. A) Enrichment of GeneGo disease using the differentially regulated
proteins between neoplastic and matched non-neoplastic samples; B) Cellular compartments, C) Biological processes, D) Molecular functions and E)
Chromosomal location of all identified proteins.
doi:10.1371/journal.pone.0042255.g002
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including GC (Figure 2A, representative of tumor versus
nontumor comparison). This supports the current data and
indicates that the findings should be further investigated to
identify or validate clinically relevant targets for the diagnosis and/
or the prognosis of GC.
The identified proteins were grouped into different classes based
on functional information available. Most of the identified proteins
were intracellular organelle proteins and were part of the
membrane-bound organelles, especially the mitochondria
(Figure 2B). These proteins are involved mainly in cellular
metabolic processes and oxidation reduction (Figure 2C). The
comparison of tumors with lymph node metastases and control
samples revealed the transport and the establishment of location as
enriched biological processes. This was not observed in the
comparison of tumors without lymph node metastases and control
samples. The oxidoreductase activity followed by coenzyme
binding activity were the main molecular functions of the proteins
involved in gastric carcinogenesis (Figure 2D).
Concerning the chromosomal location, most of the proteins
were encoded by genes located at chromosome 1 (11%),
chromosome 19 (8%), and chromosome 11 (7%) (Figure 2E).
Complex karyotypes of gastric tumors preferentially involve these
chromosomes, as well as chromosomes 3, 6, 7, 8, 13 and 17 (see
review [9]). Gain and loss of chromosome regions of 1, 19 and 11
Table 2. Top canonical pathways by Ingenuity Pathways Analysis.
Top canonical pathways p-value* Proteins
Tumor vs non-neoplastic
samples
Mitochondrial Dysfunction 5.01E-11 PDHA1, NDUFS1, ATP5B, NDUFS8, PRDX5,
NDUFS2, UQCRFS1, UQCRC1, NDUFS3, NDUFA8,
AIFM1
Pyruvate Metabolism 1.54E-10 PDHA1, AKR7A3, ALDH1A1, LIPF, AKR1B10,
ACAT1, DLD, PDHB, LDHB
Oxidative Phosphorylation 2.88E-09 NDUFS1, ATP5B, NDUFS8, ATP5H, NDUFS2,
UQCRFS1, UQCRC1, NDUFS3, PPA1, NDUFA8
Valine, Leucine and Isoleucine Degradation 4.26E-08 ALDH1A1, BCAT2, ACADVL, ACAT1, DBT, IVD,
HADH
Butanoate Metabolism 5.52E-07 PDHA1, ALDH1A1, ACAT1, DBT, PDHB, HADH
Glycolysis/Gluconeogenesis 1.05E-05 PDHA1, ALDH1A1, ENO1, DLD, PDHB, LDHB
Citrate Cycle 1.32E-05 LIPF, ACO2, DLD, IDH2
Tumor with lymph node
metastasis vs non-neoplastic
samples
Mitochondrial Dysfunction 1.67E-13 PDHA1, NDUFS1, SOD2, ATP5B, NDUFS8, PRDX5,
NDUFS2, UQCRFS1, UQCRC1, NDUFS3, NDUFA8,
AIFM1
Oxidative Phosphorylation 3.88E-10 NDUFS1, ATP5B, NDUFS8, ATP5H, NDUFS2,
UQCRFS1, UQCRC1, NDUFS3, PPA1, NDUFA8
Butanoate Metabolism 4.9E-09 PDHA1, ALDH1A1, ECHS1, ACAT1, DBT, HADH,
ACADS
Valine, Leucine and Isoleucine Degradation 1.05E-08 ALDH1A1, ECHS1, BCAT2, ACAT1, DBT, HADH,
ACADS
Pyruvate Metabolism 7.21E-07 PDHA1, AKR7A3, ALDH1A1, LIPF, AKR1B10,
ACAT1
b-alanine Metabolism 2.19E-06 DPYSL2, ALDH1A1, ECHS1, DPYSL3, ACADS
Lysine Degradation 3.16E-06 ALDH1A1, ECHS1, ACAT1, DBT, HADH
Tumor without lymph node
metastasis vs non-neoplastic
samples
Pyruvate Metabolism 1.13E-10 PDHA1, AKR7A3, ALDH1A1, LIPF, AKR1B10,
ACAT1, DLD, PDHB
Mitochondrial Dysfunction 2.94E-10 PDHA1, NDUFS1, NDUFS8, PRDX5, NDUFS2,
UQCRFS1, UQCRC1, NDUFA8, AIFM1
Butanoate Metabolism 8.22E-10 PDHA1, ALDH1A1, ACAT1, DBT, HMGCS2, PDHB,
HADH
Valine, Leucine and Isoleucine Degradation 1.77E-09 ALDH1A1, BCAT2, ACADVL, ACAT1, DBT,
HMGCS2, HADH
Citrate Cycle 3.29E-08 CS, LIPF, ACO2, DLD, IDH2
Oxidative Phosphorylation 3.98E-07 NDUFS1, NDUFS8, ATP5H, NDUFS2, UQCRFS1,
UQCRC1, NDUFA8
Glycolysis/Gluconeogenesis 7.41E-07 PDHA1, GPI, ALDH1A1, ENO1, DLD, PDHB
Tumor with lymph node
metastasis vs Tumor with
lymph node metastasis
Pentose Phosphate Pathway 5.57E-04 TALDO1, GPI
Purine Metabolism 2.71E-03 ATP5H, PPP2R4 PSMC2
Oxidative Phosphorylation 8.34E-03 ATP5H, UQCRFS1
*The p-value was calculated using the right-tailed Fisher’s Exact Test. Threshold: p,0.05.
doi:10.1371/journal.pone.0042255.t002
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were previously reported by our research group in GC samples
[43,44]. Thus, these chromosomes may contain several loci with
dosage-sensitive genes.
Networks analysis of differentially expressed proteins in
GC
We have undertaken a comprehensive computational analysis of
tissue proteomic data to discover pathways and networks involved
in gastric oncogenesis and progression. Table 2 shows the
principal canonical pathways using the Ingenuity Pathway
Analysis (IPA) database. The principal canonical pathways in the
gastric carcinogenesis process were involved in the energy
metabolism pathways including mitochondrial dysfunction, pyru-
vate metabolism, oxidative phosphorylation, citrate circle, and
glycolysis/gluconeogenesis. The present study demonstrated a
large number of differential expressed metabolic proteins that have
not been reported before in noncardia gastric carcinogenesis
(Table S1 and S2).
Our proteomic analysis revealed that several enzymes of the
citrate cycle (Krebs cycle) and of oxidative phosphorylation were
down-regulated in GC cells. These data show possible alterations
in mitochondrion function and a shift in energy production in the
present GC cells, suggesting the Warburg effect [45]. Proliferating
tumor cells reprogram their metabolic pathways to generate
energy and, thus, support the rapid cell division under stressful
metabolic conditions that are characteristic of the abnormal tumor
microenvironment [46]. Even under normal oxygen concentra-
tions, tumor cells shift from ATP generation through oxidative
phosphorylation to ATP generation through glycolysis, converting
most incoming glucose to lactate [45]. It has been proposed that
highly active glycolysis provides a biosynthetic advantage for
tumor cells. Glycolysis provides enough metabolic intermediates
by avoiding the oxidation of glucose, which is essential for the
synthesis of macromolecules, such as lipids, proteins, and nucleic
acids, during cell division [47,48,49].
The lactate dehydrogenase (LDH) and pyruvate dehydrogenase
(PDH) complexes control the metabolism of pyruvic acids,
transforming to either lactic acids or acetyl-CoA then entering
the citrate cycle. The down-regulation of subunits of the LDH and
PDH complexes suggests a reduction in pyruvate flux into the
citrate cycle and a decrease in the rate of oxidative phosphory-
lation and oxygen consumption, reinforcing the glycolytic
phenotype. Other down-regulated proteins, such as LIPF and
GOT1, highlight the activation of other metabolic pathways with
the impairment of the citrate cycle and oxidative phosphorylation.
Several metabolic alterations that we observed in noncardia GC
were also described by Cai et al. [36] in a cardia GC proteomic
study, suggesting that these metabolic alterations are not specific to
a GC subtype based on tumor location.
By the PANTHER system, the most significantly enriched
pathway is the p53 pathway observed in the comparison between
tumor and control samples. Additionally to its function in the
DNA damage response and apoptosis, p53 is also a regulator of
cell metabolism [50]. p53 promotes oxidative phosphorylation
[51] and also inhibits the glycolytic pathway by up-regulating the
expression of TP53-induced glycolysis and the apoptosis regulator
(TIGAR) [52]. Therefore, the loss of p53 contributes to the
Table 3. Top networks involved by Ingenuity Pathways Analysis.
Top network of molecular interactions and functions Score Focus proteins
Tumor vs non-neoplastic samples Cancer, Reproductive System Disease, Genetic Disorder 43 23
Cellular Assembly and Organization, Energy Production,
Nucleic Acid Metabolism
39 19
Lipid Metabolism, Small Molecule Biochemistry,
Cardiovascular Disease
29 15
Cell Death, Cancer, Cellular Development 17 10
Free Radical Scavenging, Inflammatory Disease,
Respiratory Disease
13 8
Tumor with lymph node metastasis vs
non-neoplastic samples
Cellular Assembly and Organization, Genetic Disorder,
Neurological Disease
50 22
Organismal Injury and Abnormalities, Inflammatory
Disease, Respiratory Disease
30 15
Cell Death, Antigen Presentation, Cell-To-Cell Signaling
and Interaction
27 14
Cell Death, Gastrointestinal Disease, Hepatic System Disease 25 13
Cardiac Arteriopathy, Cardiovascular Disease, Genetic Disorder 2 1
Tumor without lymph node metastasis
vs non-neoplastic samples
Genetic Disorder, Respiratory Disease, Inflammatory
Disease
30 14
Decreased Levels of Albumin, Cellular Assembly and
Organization, Dermatological Diseases and Conditions
27 13
Energy Production, Nucleic Acid Metabolism,
Small Molecule Biochemistry
24 12
Lipid Metabolism, Nucleic Acid Metabolism, Small Molecule
Biochemistry
24 12
Cardiac Arteriopathy, Cardiovascular Disease, Genetic Disorder 2 1
Tumor with lymph node metastasis vs Tumor with
lymph node metastasis
Cellular Compromise, Cell Death, Infection Mechanism 42 14
doi:10.1371/journal.pone.0042255.t003
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acquisition of glycolytic phenotype. The loss of TP53 locus is a
common finding in GC of individuals from Northern Brazil [53].
Moreover, 20% of the GC analyzed by 2-DE presented p53
immunoreactivity (data not shown). The p53 immunoreactivity
usually depends on accumulation of mutated proteins in the cell,
which leads to a longer half-life [54].
The top networks of molecular interactions and functions were
also identified using the IPA software (Figure S2; Table 3;
Subnetwork from MetaCoreTM analysis were not shown). We
showed several differently regulated proteins involved in cellular
assembly and organization, and in inflammatory processes. The
cellular assembly and organization was the principally enriched
network observed in the comparison between controls and tumors
with lymph node metastasis. Therefore, our data reveal that the
molecules of the described subnetwork are important to the
process of metastasis in noncardia gastric carcinogenesis.
Previous studies have demonstrated that GC is strongly linked
to chronic inflammation, and that infection with H. pylori may
trigger the chronic inflammation that can lead to malignancy (see
review [55]). However, the exact mechanism of this process is still
not known. The identified proteins add new pieces to this process
in gastric carcinogenesis.
Hierarchical clustering of gastric samples
The unsupervised hierarchical clustering of the differentially
expressed proteins revealed that the tumors and control samples
do not form two distinct separate clusters (Figure S3 and S4).
Although, hierarchical clustering revealed one group composed by
only controls, the other group presented all tumor samples and
two misclassified control samples. Molecular alterations may
already exist in the misclassified non-neoplastic samples resulting
from a complex interaction between H. pylori, including environ-
mental and host-genetic factors.
The group composed by tumor samples seems to present two
subgroups according to the protein expression profiling. However,
no association with clinicopathological characteristic was ob-
served.
ENO1 expression in gastric tissue
We selected ENO1 and HSPB1 genes/proteins for further
investigations. These proteins were present in the main network by
IPA analysis of differentially expressed proteins between tumor
and control samples (Figure S2-A) and were never evaluated in
GC of Brazilian individuals. Moreover, according to the IPA
database, ENO1 and HSPB1 could interact with MYC, p53 and
14-3-3 epsilon proteins (data not shown), that are frequently
deregulated in GC samples of individuals from Northern Brazil
[53,56,57,58,59,60,61].
ENO1 was also selected due to its role in the synthesis of
pyruvate [62]. The overexpression of ENO1 is associated with
tumor development through the aerobic glycolysis and it has
been described in several tumor types (see review [63]).
Additionally, ENO1 (48 kDa) is encoded by a gene which also
encodes a MYC promoter-binding protein (MBP1, 37 kDa),
using an alternative start codon. MBP1 associates with ENO1 to
inhibit the transcription of the MYC oncogenes [63]. Interest-
ingly, the MYC oncogene seems to collaborate with HIF1, a
transcription factor responsible for gene expression during the
cellular response to low oxygen conditions, in the activation of
several glucose transporters and glycolytic enzymes, contribut-
ing to the Warburg effect [46]. In the present study, MYC
immunoreactivity was observed in 67% of samples (data not
shown).
By 2-DE analysis, we observed two spots for the ENO1
(#5506 and #6505) protein that presented a higher expression
in tumors compared to the controls (Figure 3A, 3B and 3C).
Three previous proteomic studies also reported the up-regulation
Figure 3. ENO1 expression in gastric samples. A) the ratio of the sum of spot#5506 and#6505 ENO1 expression between tumor and matched
controls; B) the ratio of Spot #5506 ENO1 expression between tumor and matched controls; C) the ratio of spot #6505 ENO1 expression between
tumor and matched controls; D) Western blot using anti-ENO1 and anti-ACTB antibodies; E) the ratio of ENO1 protein expression between tumor and
matched controls by western blot analysis; F) Relative ENO1 mRNA quantification – gastric tumor samples normalized by matched controls. T: tumor
gastric sample; N: non-neoplastic gastric samples. *To calculate the ratio, 0 values (lack of a spot on the 2-DE gel) were replaced with 0.0001.
doi:10.1371/journal.pone.0042255.g003
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of ENO1 in GC samples [28,29,36] and one study described that
ENO1 was down-regulated [39]. Moreover, it was previously
demonstrated that ENO1 overexpression blocks gastrokine 1
(GKN1) induced growth inhibition and cell cycle arrest in gastric
cancer cells [64].
Here, we showed the presence of two differentially expressed
spots of ENO1 mainly in noncardia tumor samples, which suggests
PTM. Spot #6505 presented a higher expression in both tumors
with and without lymph node metastasis compared to the controls.
However, spot #5506 only differed between tumors with lymph
node metastases and controls. Cai et al. [36] also reported the up-
regulation of two spots of ENO1 in cardia GC. PTM of ENO1 has
been reported in several cancers and normal cell lines (see review
[63]). Capello et al. [63] suggested that PTMs are important
mechanisms in the regulation of ENO1 function, localization, and
immunogenicity.
Inversely to the 2-DE observation, the protein level of ENO1
showed a 1.5 fold reduction in 35.3% of GC samples compared to
their paired controls (Figure 3E and 3F) by western blot. Only one
sample presented a 1.5 fold increase. However, we only selected
the spots differentially expressed with a 1.5 fold change between
groups for the mass spectrometry analysis. These selection criteria
may lead to the lack of correlation between western blot and
proteomic analyses. Thus, other spots of ENO1 may present a
slight reduced expression, but with a high impact in the mean of
this protein expression. Our results show that different spots may
be regulated differently inside a heterogeneous gastric sample. Our
findings also highlight that the metabolic phenotype is not
universal in tumor cells [65], especially considering that different
cell clones are present inside a single cancer sample. Even in
glycolytic tumors, oxidative phosphorylation is not completely shut
down. Owing to the dynamic nature of the tumor microenviron-
ment, it is suggested that the metabolic phenotype of tumor cells
changes to adapt to the prevailing local conditions [46]. The
regulation of this metabolic flexibility is poorly understood.
However, the feedback control between MYC and ENO1, as well
as MBP1, may have a key role in this process since the MYC
oncogene may stimulate both glycolysis and oxidative phosphor-
ylation.
In the present study, the mRNA level of ENO1 showed a 1.5
fold reduction in 35.3% and increased in 58.8% of GC samples
compared to their paired control (Figure 3G). No correlation was
observed between the ENO1 mRNA and protein level detected by
western Blot (r=0.219; p= 0.397). The mRNA level was
correlated only to the expression of ENO1 spot #6505 by 2-DE
analysis (r=0.378, p-0.043). However, the ENO1 gene encodes
ENO1 and MBP1 proteins. The MBP1 cDNA shares 97%
similarity with the cDNA encoding the isoform of the glycolytic
enzyme enolase [66]. Thus, the analysis of ENO1 mRNA
expression reflects only in part the ENO1 expression. On the
Table 4. Clinicopathological characteristics, ENO1 and HSPB1 expression in gastric cancer samples.
ENO1 protein ENO1 mRNA HSPB1 protein HSPB1 mRNA
Variable N
Ratio T/N
(Mean±SD) p-value N
RQ
(Mean±SD) p-value N
Ratio T/N
(Mean±SD) p-value N
RQ
(Mean±SD) p-value
Gender
Male 8 0.6360.41 0.302 14 1.8461.52 0.327 9 18.17631.02 0.504 18 1.6461.28 0.803
Female 10 0.8060.63 12 1.3161.05 10 10.32618.06 13 1.8863.667
Onset (years)
,45 5 0.6860.24 0.762 7 1.2160.75 0.386 5 20.10642.21 0.691 8 1.0960.55 0.403
$45 13 0.7460.37 19 1.7461.48 14 11.87616.53 23 1.9762.89
Tumor location
Cardia 2 0.5260.25 0.383 3 1.0260.76 0.438 3 34.98652.68 0.500 4 0.9260.65 0.495
Non-cardia 16 0.7560.34 23 1.6761.38 16 10.11615.95 27 1.8662.68
Histological subtype
Diffuse-type 4 0.4860.28 0.103 10 1.4461.01 0.651 4 1.8961.26 0.279 13 1.4361.47 0.572
Intestinal-type 14 0.7960.32 16 1.6961.52 15 17.27626.96 18 1.9663.09
Stage
Early 4 0.5760.40 0.308 4 1.0960.56 0.421 4 6.8767.69 0.529 4 1.2460.80 0.678
Advanced 14 0.7760.31 22 1.6961.41 15 15.94627.37 27 1.8262.69
Tumor invasion
T1/T2 7 0.5660.37 0.910 8 1.1560.62 0.259 7 4.5166.21 0.114 9 1.3360.70 0.567
T3/T4 11 0.8360.27 18 1.8061.52 12 19.59629.68 22 1.9162.96
Lymph node metastasis
Absent 6 0.7560.43 0.798 7 0.9260.49 0.119 6 5.2466.50 0.304 8 1.0760.69 0.391
Present 12 0.7160.29 19 1.8461.46 13 18.09628.92 23 1.9762.88
Distant metastasis
Unknown/absent 15 0.7160.35 0.746 20 1.3960.93 0.361 15 14.15627.30 0.955 23 1.3961.17 0.432
Present 3 0.7860.25 6 2.3062.18 4 13.60612.83 8 2.7664.62
RQ: relative quantification; T: tumor gastric samples; N: non-neoplastic gastric samples.
doi:10.1371/journal.pone.0042255.t004
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other hand, Cai et al. [36] reported an increase of ENO1 mRNA
and protein expression in cardia GC samples by RT-qPCR
(primers for cDNA of ENO1 and MBP1) and western blot, but no
statistical analysis was performed, making it difficult to formulate a
direct comparison with our results.
Table 4 summarizes the associations between clinicopatholog-
ical characteristics and ENO1 expression. The 1.5 fold reduction
of ENO1 protein expression was more frequently observed in
tumors in the T1/T2 stage than the T3/T4 stage (71.4% vs
28.6%; x2 = 5.103, df = 1, p = 0.039; OR=11.25). Few studies are
aimed to a better understanding of the role of ENO1 in gastric
carcinogenesis. Bai et al. [28], who described an up-regulated spot
of ENO1, did not find a significant difference between tumor and
non-neoplastic samples by western blot analysis. However, these
authors described that ENO1 immnuoreactivity seems to be
significantly more intense in GC cells than non-neoplastic cells and
its positive expression tends to be associated with poor prognosis.
This in part corroborates our results that demonstrate that the
level of ENO1 protein seems to be reduced more frequently in less
invasive cancer samples.
HSBP1 expression in gastric tissue
HSPB1 was selected for further investigation also due to its
protective function against infection and cellular stress. HSPB1 is
one member of the family of heat shock proteins (HSP) that is
characterized as molecular chaperones. In addition to its
chaperone function, HSPB1 also seems to be an important
regulator of structural integrity and membrane stability, actin
polymerization and intermediate filament cytoskeleton formation,
cell migration, epithelial cell-cell adhesion, cell cycle progression,
proinflammatory gene expression, muscle contraction, signal
transduction pathways, mRNA stabilization, presentation of
oxidized proteins to the proteasome, differentiation, and apoptosis
[67].
HSPB1 is highly induced by different stresses such as heat,
oxidative stress, or anticancer drugs. In non stressed cells, HSPB1
is not expressed or at very low levels. Once induced, HSPB1 acts
at multiple points in the apoptotic pathways to ensure that stress-
induced damage does not inappropriately trigger cell death [68].
Many cancer cells have markedly increased HSPB1 levels, and this
protein expression contributes to the malignant properties of these
cells, including increased tumorigenicity and treatment resistance,
and apoptosis inhibition [67]. Overexpression of HSPB1 has been
described in several tumors and it has been reported as an
indicator of poor prognosis (see review [69]). Elevated HSPB1
expression in neoplastic cells plays a key role in protection from
spontaneous apoptosis in response to anticancer therapy and
leading to tumor progression and resistance to treatment [69].
In the present study, we observed one spot of the HSPB1
protein that presented a higher expression in GC compared to
controls by 2-DE analysis (Figure 4A), corroborating previously
proteomic studies with GC patients from Asiatic countries
[24,28,33,34,35,36,39].
By Western blot analysis, the protein level of HSPB1 was 1.5
fold higher in 68.4% of GC samples compared to their paired
controls and 1.5 fold lower in 21.1% of the samples (Figure 4B and
4C). The HSPB1 mRNA level was 1.5 fold higher in 38.7% and
reduced in 32.3% of tumors compared to controls (Figure 4D).
Previous studies also described a high expression of HSPB1 in
Figure 4. HSPB1 expression in gastric samples. A) the ratio of spot #4203 HSPB1 expression between tumor and matched controls; B) western
blot using anti-HSPB1 and anti-ACTB antibodies; C) the ratio of HSPB1 protein expression between tumor and matched controls by western blot
analysis; D) Relative HSPB1 mRNA quantification – gastric tumor samples normalized by matched controls. T: tumor gastric sample; N: non-neoplastic
gastric samples.
doi:10.1371/journal.pone.0042255.g004
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about 50% of GC by immunohistochemistry in other populations
[70,71,72,73].
The increase in the HSPB1 mRNA level was correlated with the
protein expression observed by 2-DE analysis (r=0.601,
p = 0.018). Additionally, we observed a correlation between the
increase of 1.5 fold in mRNA and protein levels by western blot
(r=0.54; p = 0.025). The lack of strong correlation between
HSPB1 protein and mRNA expression patterns indicates the post-
translational regulation mechanism involved in this protein
expression and highlights the complexity of the relationship
between protein and mRNA expression.
No correlation was observed between the HSPB1 protein level
detected by western blot and 2-DE analysis (r=0.075; p = 0.792).
However, it is possible to verify that the fold changes of HSPB1 by
2-DE analysis (range of 0.79 to 11.86) is lower than that observed
by western blot analysis (range of 0.15 to 95.59), suggesting that
the other HSPB1 isoforms (with the same molecular weight) are
also recognized by the anti-HSPB1 monoclonal antibody. These
isoforms may be differentially regulated in GC of individuals from
Northern Brazil, which may lead to the lack of correlation between
these two methodologies. This hypothesis is supported by Cai et al.
in a study [36] in which two differentially regulated spots of
HSPB1 were detected in cardia GC. The authors observed that
the mean of HSPB1 expression was elevated in tumors compared
to non-neoplastic tissue.
Here, no association was observed among HSPB1 expression
and clinicopathological characteristics in the present study
(Table 4). However, HSPB1 was previously associated with gastric
tumor size, distant metastasis, lymph node state and pStage in
other populations [70,71,72,73]. Despite the fact that HSPB1
expression was not associated with any clinicopathological
characteristic in our population, we hypothesized that HSPB1,
especially the isoform detected by 2-DE analysis, may have a role
in the carcinogenesis process in a subset of tumors due to the
higher expression observed in several GC samples.
In addition, since HSPB1 contributes to chemotherapy resis-
tance and apoptosis inhibition in gastric cancer cells [74], the high
levels of HSPB1 observed in our GC sample might be associated
with anticancer drug resistance or survival, as well as poor patient
prognosis. The lack of additional information about the survival or
response to any adjuvant treatment from the studied patients is
one limitation of this study.
Conclusion
Our differential proteomic analysis revealed several potential
proteins that are deregulated in noncardia GC of individuals
from Northern Brazil. For the identification of differentially
expressed proteins we controlled the type I error that is a main
issue in multiple comparison analyses using bootstrapping
resampling. The cancer-associated proteins could be useful for
GC diagnosis or prognosis. Several identified proteins reinforce
the Warburg effect, suggesting active glycolysis in neoplastic cells.
Therapeutic approaches targeting glycolytic process may be an
interesting future for GC treatment. On the other hand, the
analysis of ENO1 expression highlights that the metabolic
phenotype may be dynamic in GC samples. Although further
investigations are necessary, HSPB1 may have a role in a subset
of GC samples. Our results also underline the complex control of
mRNA and protein expression. The present study will enhance
efforts to generate and expand knowledge about gastric carcino-
genesis and in doing so, aid in the discovery of more reliable
diagnosis for malignancies of the stomach in the Brazilian
population.
Supporting Information
Figure S1 14 significantly different proteins between
tumors with and without lymph node metastasis. The
normalized means (z-scores) of the expression in non-neoplastic,
neoplastic without [T(N2)] and with lymph node metastasis
[T(N+)] is presented.
(TIF)
Figure S2 Protein-protein physical/functional interac-
tion subnetworks in gastric carcinogenesis by generated
Ingenuity Pathway Analysis tool. A) Cancer subnetwork
revealed in the analysis of differentially expressed proteins between
neoplastic and matched controls; B) Cellular assembly and
organization, energy production, nucleic acid metabolism subnet-
work revealed in the analysis of differentially expressed proteins
between neoplastic and matched controls; C) Cellular assembly
and organization subnetwork revealed in the analysis of differen-
tially expressed proteins between controls and tumors with lymph
node metastasis; D) Inflammatory subnetwork revealed in the
analysis of differentially expressed proteins between controls and
tumors without lymph node metastasis. Red: up-regulated
proteins; Green: down-regulated proteins.
(TIF)
Figure S3 Differentially expressed by paired T-test
analysis. Heat map represents the expression protein
level. The samples are shown vertically and the proteins
horizontally. Higher expressions are colored red, the lower ones
in green. The dendrograms represent the distances between the
clusters.
(TIF)
Figure S4 Differentially expressed by one-way ANOVA
analysis. Heat map represents the expression protein
level. The samples are shown vertically and the proteins
horizontally. Higher expressions are colored red, the lower ones
in green. The dendrograms represent the distances between the
clusters.
(TIF)
Table S1 Differentially expressed proteins between
neoplastic and non-neoplastic gastric samples by paired
T-test analysis.
(DOCX)
Table S2 Differentially expressed proteins among non-
neoplastic gastric samples, neoplastic without lymph
node metastasis and neoplastic with lymph node
metastasis by ANOVA one-way analysis.
(DOCX)
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